Full Text View
Tabular View
No Study Results Posted
Related Studies
Mucin in Sputum of CF During Pulmonary Exacerbation
This study is currently recruiting participants.
Verified by Philipps University Marburg Medical Center, September 2005
First Received: September 12, 2005   No Changes Posted
Sponsored by: Philipps University Marburg Medical Center
Information provided by: Philipps University Marburg Medical Center
ClinicalTrials.gov Identifier: NCT00202072
  Purpose

The purpose of this study is to determine whether mucin is increased during pulmonay exacerbations in adult patients with cystic fibrosis (CF).


Condition
Cystic Fibrosis

Genetics Home Reference related topics: cystic fibrosis
MedlinePlus related topics: Cystic Fibrosis
U.S. FDA Resources
Study Type: Observational
Study Design: Natural History, Longitudinal, Defined Population, Retrospective Study

Further study details as provided by Philipps University Marburg Medical Center:

Estimated Enrollment: 25
Study Start Date: January 2004
Estimated Study Completion Date: September 2005
Detailed Description:

CF is typically associated with mucus hypersecretion in the airways. In health, mucin is the major macromolecular component and is responsible for the protective and clearance properties of the mucus gel. In a recent study we found that mucins are decreased in the sputum of adult CF patients.

In this study we want to investigate the differences on the mucin and DNA quantity and quality of airway secretions in during pulmoanry exacerbation.We hypothesize that during an exacerbation the mucin and DNA amount is increasing. The aim of this study is to evaluate the molecular (mucins) and structure properties (mucin-DNA-network) of the airway secretions in CF related to the severity of the disease. We characterize sputum composition of patients with pulmonary exacerbations. Using gel electrophoresis and dot-blot with specific antibodies we will analyze MUC5AC and MUC5B mucins. DNA amount will be measured by microfluorimetry.

With the laser scanning confocal microscopy the mucin-DNA-network will be evaluated.

The significance of these studies is that they will give us novel information about the pathogenesis of chronic inflammatory airway diseases, provide tools for assessing the progression of lung disease, and most critically, will identify novel opportunities and targets for therapeutic intervention.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • cystic fibrosis
  • chronic pseudomonas aeruginosa inflammation
  • pulmonary exacerbation

Exclusion Criteria:

-

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00202072

Contacts
Contact: Markus O Henke, MD 06421 ext 2866041 markus.henke@staff.uni-marburg.de

Locations
Germany
Pediatric department, CF center, University Giessen Recruiting
Giessen, Germany
Contact: Hermann Lindemann, MD     0641/99 ext 43430     Hermann.Lindemann@paediat.med.uni-giessen.de    
Pediatric department, CF center, University Marburg Recruiting
Marburg, Germany
Contact: Markus O Henke, MD     06421 ext 2866041     markus.henke@staff.uni-marburg.de    
Sponsors and Collaborators
Philipps University Marburg Medical Center
Investigators
Principal Investigator: Markus O Henke, MD Philipps University Marburg Medical Center
  More Information

Publications:
Study ID Numbers: 208/03
Study First Received: September 12, 2005
Last Updated: September 12, 2005
ClinicalTrials.gov Identifier: NCT00202072     History of Changes
Health Authority: Germany: Ethics Commission

Keywords provided by Philipps University Marburg Medical Center:
lung
airway
pulmonary exacerbation
mucus

Study placed in the following topic categories:
Digestive System Diseases
Genetic Diseases, Inborn
Respiratory Tract Diseases
Cystic Fibrosis
Fibrosis
Lung Diseases
Infant, Newborn, Diseases
Pancreatic Diseases

Additional relevant MeSH terms:
Pathologic Processes
Digestive System Diseases
Genetic Diseases, Inborn
Respiratory Tract Diseases
Cystic Fibrosis
Fibrosis
Lung Diseases
Infant, Newborn, Diseases
Pancreatic Diseases

ClinicalTrials.gov processed this record on May 07, 2009